Knowledge Ecology International

Printer-friendly version
Seventy-second World Health Assembly (A72/1)
Agenda Item: 
11.7 Access to medicines and vaccines

KEI supports the adoption of a strong transparency resolution that addresses every topic in the original May 20th proposal (A72/A/CONF./2), including prices, revenues, units sold, marketing costs, clinical trial enrollment and outcomes, clinical trial costs, government R&D subsidies, patent landscapes, manufacturing know-how, and future meetings, forums and activities that collectively are designed to progressively expand and implement norms on transparency.

The transparency resolution is designed to level the playing field, and to end the asymmetric access to information that exists today, with drug companies knowing everything and the public only knowing what drug companies want us to think.

The disclosure of clinical trial costs, the major R&D cost factor and one that is straightforward to assign to specific products, has been the most controversial issue. Drug companies are concerned that if the actual costs are disclosed, narratives about massive R&D costs will be undermined, by facts, for a number of products.

There are several reasons why governments and the public need access to reliable information about trials costs, which are described in here: